EGFR and interstitial lung disease: The association appeared to be specific for osimertinib, as administration of first or second-generation TKIs immediately after nivolumab did not increase the risk of ILD [39], and no trAEs were observed when PD-L1 blockers were followed by other EGFR-TKIs [37,71].